Analysts forecast that Five Prime Therapeutics Inc (NASDAQ:FPRX) will report $9.86 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Five Prime Therapeutics’ earnings. The highest sales estimate is $11.71 million and the lowest is $8.00 million. Five Prime Therapeutics posted sales of $8.26 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 19.4%. The firm is scheduled to issue its next earnings report on Thursday, February 22nd.
According to Zacks, analysts expect that Five Prime Therapeutics will report full-year sales of $9.86 million for the current fiscal year, with estimates ranging from $34.30 million to $42.00 million. For the next financial year, analysts expect that the company will post sales of $25.67 million per share, with estimates ranging from $20.00 million to $30.00 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.19). Five Prime Therapeutics had a negative net margin of 408.42% and a negative return on equity of 41.57%. The business had revenue of $8.33 million for the quarter, compared to analysts’ expectations of $16.16 million. During the same period in the prior year, the business earned ($0.72) earnings per share. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year.
Several research analysts have recently weighed in on the company. Zacks Investment Research upgraded Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 price target for the company in a research note on Monday, October 16th. Royal Bank of Canada increased their price target on Five Prime Therapeutics from $41.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, November 6th. BMO Capital Markets increased their price target on Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 7th. Jefferies Group reiterated a “buy” rating and set a $52.00 price target on shares of Five Prime Therapeutics in a research note on Tuesday, September 12th. Finally, ValuEngine downgraded Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. Five Prime Therapeutics presently has an average rating of “Buy” and a consensus price target of $64.00.
Shares of Five Prime Therapeutics (FPRX) traded down $0.59 during trading on Tuesday, hitting $21.92. The stock had a trading volume of 305,100 shares, compared to its average volume of 421,849. Five Prime Therapeutics has a 1 year low of $19.73 and a 1 year high of $52.98. The stock has a market cap of $651.22, a price-to-earnings ratio of -4.32 and a beta of 3.90.
In other Five Prime Therapeutics news, Director William R. Ringo sold 600 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $45.33, for a total value of $27,198.00. Following the completion of the transaction, the director now owns 600 shares in the company, valued at approximately $27,198. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 6.50% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of FPRX. Oppenheimer & Co. Inc. bought a new position in Five Prime Therapeutics in the 3rd quarter worth about $223,000. Legal & General Group Plc boosted its stake in Five Prime Therapeutics by 3.1% in the 2nd quarter. Legal & General Group Plc now owns 9,455 shares of the biotechnology company’s stock worth $288,000 after purchasing an additional 287 shares during the period. Virtu KCG Holdings LLC bought a new stake in shares of Five Prime Therapeutics during the 2nd quarter valued at about $331,000. Dupont Capital Management Corp bought a new stake in shares of Five Prime Therapeutics during the 3rd quarter valued at about $341,000. Finally, Tudor Investment Corp ET AL boosted its position in shares of Five Prime Therapeutics by 49.4% during the 2nd quarter. Tudor Investment Corp ET AL now owns 11,999 shares of the biotechnology company’s stock valued at $361,000 after acquiring an additional 3,966 shares during the last quarter. Institutional investors and hedge funds own 83.66% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/01/17/five-prime-therapeutics-inc-fprx-expected-to-announce-quarterly-sales-of-9-86-million.html.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.